Rasio rega marang prakiraan pendapatan Invivyd (IVVD)

invivyd.com - logo grafis emiten IVVD

Invivyd, Inc. (IVVD) relies on external contractors for antibody testing and is implementing robotics for 24/7 drug screening. The forward price-to-sales valuation trend demonstrates volatility, with the 2.90 mark indicating the current valuation level. High business scalability allows the company to rapidly capture the global market with minimal production costs following drug approval.

IVVD (Invivyd) riwayat Rasio rega marang prakiraan pendapatan saka 16.08.2024 nganti 13.11.2026

invivyd.com (IVVD) - rincian metrik lan laporan keuangan

- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
Analisis wiwitan perusahaan:Invivyd Corp IVVD
Produk sing diprodhuksi Invivyd Inc

The investment attractiveness of Invivyd, Inc. (IVVD) relies on the stability of its scientific core and expertise in securing FDA antibody approvals. This metric evaluates the ratio of current market capitalization to expected sales, determining the asset's margin of safety through projected P/S dynamics. A decline in this ratio, while maintaining the human capital potential of the Discovery platform, may indicate that the business is undervalued relative to its fundamental prospects.

Analisis pesaing Invivyd, Inc.

Multiplikator Forward P/S GILD (Gilead Sciences)|Rasio kapitalisasi marang dodolan sing dikarepake Cidara Therapeutics Corp (CDTX)|NVAX - Rasio rega marang prakiraan pendapatan|CVAC (CureVac Pharma) - Kapitalisasi marang prakiraan pendapatan|VALN (Valneva SE) - Multiplikator forward rega marang pendapatan|VIR (vir.bio) - Rasio rega marang prakiraan pendapatan|SIGA (SIGA Technologies) - Multiplikator Forward P/S|Emergent BioSolutions Inc (EBS) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan AVIR (Atea Pharmaceuticals Inc)|Rasio rega marang prakiraan pendapatan ENTA (Enanta Pharmaceuticals, Inc)|Inovio Pharmaceuticals - Multiplikator forward rega marang pendapatan|hillevax.com (HLVX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Kalaris Therapeutics - Multiplikator Forward P/S|DYAI (Dyadic International) - Kapitalisasi marang prakiraan pendapatan|NNVC (nanoviricides.com) - Multiplikator forward rega marang pendapatan|Talphera Corporation - Rega forward marang dodolan|COCP (Cocrystal Pharma, Inc.) - Multiplikator Forward P/S|Traws Therapeutics (TRAW) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Dogwood Therapeutics, Inc. (DWTX)|Qualigen Therapeutics Inc - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S ALVR (AlloVir)|VBIV - Multiplikator forward rega marang pendapatan|VIRI: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Vaxart, Inc. VXRT